All News
Don’t be ‘ticked’: TYK2 is not a JAK!
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Read Article
So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m
David Liew drdavidliew ( View Tweet)
Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir
TheDaoIndex KDAO2011 ( View Tweet)
Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients
◦ Physical examination is meaningful and cannot be replaced by technology
◦ Don’t treat the EHR, treat the patient
◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw
Dr. Antoni Chan synovialjoints ( View Tweet)
@MayoClinic data for bari in relapsing GCA caused waves at #ACR21
Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes
waiting for SELECT-GCA with interest! @EBRheum
ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3
David Liew drdavidliew ( View Tweet)
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Eric Dein ericdeinmd ( View Tweet)
⬆️ correlation between BASDAI + ASQoL in 🙋♂️ vs 🙋♀️
What does this mean?
❓low disease activity in 🙋♀️ resulting in more marked ⬇️ in QoL❓
OR
❓Is there a need for gender stratified tools of disease activity❓
Abst#0406
#ACR22 @RheumNow @Sineadm15
Patricia Harkins DrTrishHarkins ( View Tweet)
A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD
Great review slide for trainees!
#ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8
sheila RHEUMarampa ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Dr. Rachel Tate uptoTate ( View Tweet)
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy
🔸Ovarian cancer - most common
Really important to do cancer screening in #dermatomyositis
#ACR22 @RheumNow https://t.co/jErqcR0Gyr
sheila RHEUMarampa ( View Tweet)
Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview
@rheumnow #ACR22 https://t.co/luxDDluddM
TheDaoIndex KDAO2011 ( View Tweet)
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Janet Pope Janetbirdope ( View Tweet)
OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line.
1/2 switch JAKi->TNFi
1/3 switch JAKi ->JAKi
Why high proportion of JAKi cycling, when AE reason for switch low?
https://t.co/APdWW7fzJE
Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI
Aurelie Najm AurelieRheumo ( View Tweet)
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
Eric Dein ericdeinmd ( View Tweet)
TCZ in GCA: what does it mean for diabetes?
post-hoc GiACTA:
HbA1c obvs better with TCZ (PNL dosing)
but then: even after adjusting for PNL dose, apparent benefit
Is there protective effect?
Interesting observation worth investigating
ABST0461 @MGHrheumatology #ACR22 @RheumNow https://t.co/CF1as5y7Yy
David Liew drdavidliew ( View Tweet)
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Yr in Review. John Varga says novel vaccination immune therapy may reverse #fibrosis - at least in mice. Hope for #scleroderma & other fibrotic diseases. Data need to be transferred into human experiments @RheumNow https://t.co/ybFRXheQq3
Janet Pope Janetbirdope ( View Tweet)
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH
7.3% had "severe non-adherence" by HCQ levels
Hazard ratio of flare 3.3, damage 4.26, and death 5.4
Not surprising, but very useful for pt discussion
Checking HCQ levels are helpful!
@Rheumnow https://t.co/S7P9oTPRGJ
Eric Dein ericdeinmd ( View Tweet)
Study showing Evusheld can protect our patients who are immunosuppressed; it saved alot of live. One of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/6ekWvA6Ruw
TheDaoIndex KDAO2011 ( View Tweet)
ACR Year in review J. Varga
What drives TNF superproduction in RA?
Study mice 🐁 model grafted w/ human synovial tissue suggests
important role of mitochondrial stress through aspartate deficiency
A potential new therapeutic target 🎯 RA?
@RheumNow #ACR22 #ACRyearinreview https://t.co/lKrOn05sFp
Aurelie Najm AurelieRheumo ( View Tweet)